he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Ivacaftor Tablets had estimated annual sales of USD 109 million in the US.
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
The product will be launched by NATCO's commercial partner Viatris.
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
Perrigo expects to launch Omeprazole Minis later this year
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
ICICI Direct expects revenue CAGR of 35.6% over FY22-FY24E mainly due to the consolidation of Viatris business and they expect EBITDA margin expansion of 230bps and earnings CAGR of 64.8% over FY22-FY24E
Subscribe To Our Newsletter & Stay Updated
